Evidence map›Paper›PMID 33568787›Full record

ArticleOncogene2021

Correction to: Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.

Guanwen Wang, Juan Wang, Antao Chang, Dongmei Cheng, Shan Huang, Dan Wu, Sherona Sirkisoon, Shuang Yang, Hui-Kuan Lin, Hui-Wen Lo and 2 more

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Guanwen Wang *Department of Immunology, School of Medicine, Nankai University, Tianjin, China.
Juan Wang *Department of Immunology, School of Medicine, Nankai University, Tianjin, China.
Antao ChangDepartment of Immunology, School of Medicine, Nankai University, Tianjin, China.
Dongmei ChengDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Shan HuangDepartment of Immunology, School of Medicine, Nankai University, Tianjin, China.
Dan WuDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Sherona SirkisoonDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Shuang YangDepartment of Immunology, School of Medicine, Nankai University, Tianjin, China.
Hui-Kuan LinDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.ORCID http://orcid.org/0000-0002-3501-2410
Hui-Wen LoDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.ORCID http://orcid.org/0000-0002-0681-7914
Rong XiangDepartment of Immunology, School of Medicine, Nankai University, Tianjin, China. rxiang@nankai.edu.cn.ORCID http://orcid.org/0000-0003-3487-7348
Peiqing SunDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA. psun@wakehealth.edu.ORCID http://orcid.org/0000-0003-2255-6504
Atrium Health Wake Forest Baptist · USNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33568787
OpenAlexW3089712320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.